Unknown

Dataset Information

0

Pt(iv) derivatives of cisplatin and oxaliplatin bearing an EMT-related TMEM16A/COX-2-selective dual inhibitor against colorectal cancer cells HCT116.


ABSTRACT: Colorectal cancer represents the over-expression of TMEM16A and COX-2, offering a promising therapeutic strategy. Two Pt(iv) conjugates derived from Pt(ii) drug (cisplatin or oxaliplatin) and niflumic acid, complexes 1 and 2, were designed and prepared to exert the positive impact of multiple biological targets of DNA/TMEM16A/COX-2 against colorectal cancer. Complex 2 afforded higher cytotoxicity than 1 and the combination of an intermediate of oxidized oxaliplatin and NFA against cancer cells A549, HeLa, MCF-7, and HCT116. Especially for colorectal cancer cells HCT116, 2 was significantly more toxic (22-fold) and selective to cancer cells against normal HUVEC cells (4-fold) than first-line oxaliplatin. The outstanding anticancer activity of 2 is partly attributed to its dramatic increase in cellular uptake, DNA damage, and apoptosis. Mechanistic studies indicated that 2 inhibited HCT116 cell metastasis by triggering TMEM16A, COX-2, and their downstream signaling pathways, including EGFR, STAT3, E-cadherin and N-cadherin.

SUBMITTER: Ma ZY 

PROVIDER: S-EPMC11342162 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pt(iv) derivatives of cisplatin and oxaliplatin bearing an EMT-related TMEM16A/COX-2-selective dual inhibitor against colorectal cancer cells HCT116.

Ma Zhong-Ying ZY   Ding Xiao-Jing XJ   Zhu Zhen-Zhen ZZ   Chen Qian Q   Wang Dong-Bo DB   Qiao Xin X   Xu Jing-Yuan JY  

RSC medicinal chemistry 20240801


Colorectal cancer represents the over-expression of TMEM16A and COX-2, offering a promising therapeutic strategy. Two Pt(iv) conjugates derived from Pt(ii) drug (cisplatin or oxaliplatin) and niflumic acid, complexes 1 and 2, were designed and prepared to exert the positive impact of multiple biological targets of DNA/TMEM16A/COX-2 against colorectal cancer. Complex 2 afforded higher cytotoxicity than 1 and the combination of an intermediate of oxidized oxaliplatin and NFA against cancer cells A  ...[more]

Similar Datasets

| S-EPMC11770746 | biostudies-literature
| S-EPMC10549245 | biostudies-literature
| S-EPMC5944384 | biostudies-literature
| S-EPMC7132275 | biostudies-literature
| S-EPMC6964279 | biostudies-literature
| S-EPMC10304174 | biostudies-literature
| S-EPMC10094171 | biostudies-literature
| S-EPMC5540250 | biostudies-other
| S-EPMC4241752 | biostudies-literature
| S-EPMC5602572 | biostudies-literature